Literature DB >> 24374003

Solvent induced phase inversion-based in situ forming controlled release drug delivery implants.

Raghu Raj Singh Thakur1, Hannah L McMillan2, David S Jones2.   

Abstract

In situ forming (ISF) drug delivery implants have gained tremendous levels of interest over the last few decades. This is due to their wide range of biomedical applications such as in tissue engineering, cell encapsulation, microfluidics, bioengineering and drug delivery. Drug delivery implants forming upon injection has shown a range of advantages which include localized drug delivery, easy and less invasive application, sustained drug action, ability to tailor drug delivery, reduction in side effects associated with systemic delivery and also improved patient compliance and comfort. Different factors such as temperature, pH, ions, and exchange of solvents are involved in in situ implant formation. This review especially focuses on ISF implants that are formed through solvent induced phase inversion (SPI) technique. The article critically reviews and compares a wide range of polymers, solvents, and co-solvents that have been used in SPI implant preparation for control release of a range of drug molecules. Major drawback of SPI systems has been their high burst release. In this regard, the article exhaustively discusses factors that affect the burst release and different modification strategies that has been utilised to reduce the burst effect from these implants. Performance and controversial issues associated with the use of different biocompatible solvents in SPI systems is also discussed. Biodegradation, formulation stability, methods of characterisation and sterilisation techniques of SPI systems is comprehensively reviewed. Furthermore, the review also examines current SPI-based marketed products, their therapeutic application and associated clinical data. It also exemplifies the interest of multi-billion dollar pharma companies worldwide for further developments of SPI systems to a range of therapeutic applications. The authors believe that this will be the first review article that extensively investigate and discusses studies done to date on SPI systems. In so doing, this article will undoubtedly serve as an enlightening tool for the scientists working in the concerned area.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Controlled release; Drug delivery; In situ forming implants; Solvent induced phase inversion implants; Sustained release

Mesh:

Substances:

Year:  2013        PMID: 24374003     DOI: 10.1016/j.jconrel.2013.12.020

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  10 in total

1.  Noninvasive characterization of in situ forming implant diffusivity using diffusion-weighted MRI.

Authors:  Kelsey A Hopkins; Nicole Vike; Xin Li; Jacqueline Kennedy; Emma Simmons; Joseph Rispoli; Luis Solorio
Journal:  J Control Release       Date:  2019-07-16       Impact factor: 9.776

2.  Preparation and in vitro evaluation of injectable formulations of levothyroxine sodium using in situ forming hydrogel temperature-responsive systems based on PLA-PEG-PLA and PLGA-PEG-PLGA triblock copolymers.

Authors:  Jebraeil Movaffagh; Farzin Hadizadeh; Elham Khodaverdi; Bahnaz Khalili; Seyedeh Nesa Rezaeian Shiadeh; Hossein Kamali; Fatemeh Oroojalian
Journal:  Iran J Basic Med Sci       Date:  2022-03       Impact factor: 2.532

3.  In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide.

Authors:  Ravi Sheshala; Gan Chew Hong; Wong Pui Yee; Venkata Srikanth Meka; Raghu Raj Singh Thakur
Journal:  Drug Deliv Transl Res       Date:  2019-04       Impact factor: 4.617

4.  An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems.

Authors:  Dileep R Janagam; Lizhu Wang; Suryatheja Ananthula; James R Johnson; Tao L Lowe
Journal:  Pharmaceutics       Date:  2016-09-01       Impact factor: 6.321

5.  Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson's disease.

Authors:  Ying Jiang; Xuemei Zhang; Hongjie Mu; Hongchen Hua; Dongyu Duan; Xiuju Yan; Yiyun Wang; Qingqing Meng; Xiaoyan Lu; Aiping Wang; Wanhui Liu; Youxin Li; Kaoxiang Sun
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

6.  Dual-Drug Delivery via Zein In Situ Forming Implants Augmented with Titanium-Doped Bioactive Glass for Bone Regeneration: Preparation, In Vitro Characterization, and In Vivo Evaluation.

Authors:  Alaa Emad Eldeeb; Salwa Salah; Mostafa Mabrouk; Mohammed S Amer; Nermeen A Elkasabgy
Journal:  Pharmaceutics       Date:  2022-01-24       Impact factor: 6.321

7.  Smart phase transformation system based on lyotropic liquid crystalline@hard capsules for sustained release of hydrophilic and hydrophobic drugs.

Authors:  Xuejuan Zhang; Yujun Xiao; Zhengwei Huang; Jintian Chen; Yingtong Cui; Boyi Niu; Ying Huang; Xin Pan; Chuanbin Wu
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

8.  Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery.

Authors:  S Rahima Benhabbour; Martina Kovarova; Clinton Jones; Daijha J Copeland; Roopali Shrivastava; Michael D Swanson; Craig Sykes; Phong T Ho; Mackenzie L Cottrell; Anush Sridharan; Samantha M Fix; Orrin Thayer; Julie M Long; Daria J Hazuda; Paul A Dayton; Russell J Mumper; Angela D M Kashuba; J Victor Garcia
Journal:  Nat Commun       Date:  2019-09-20       Impact factor: 14.919

9.  Effect of Polymer Permeability and Solvent Removal Rate on In Situ Forming Implants: Drug Burst Release and Microstructure.

Authors:  Xiaowei Zhang; Liqun Yang; Chong Zhang; Danhua Liu; Shu Meng; Wei Zhang; Shengnan Meng
Journal:  Pharmaceutics       Date:  2019-10-10       Impact factor: 6.321

Review 10.  Drug delivery for bioactive polysaccharides to improve their drug-like properties and curative efficacy.

Authors:  Zhe Li; LiNa Wang; Xiao Lin; Lan Shen; Yi Feng
Journal:  Drug Deliv       Date:  2017       Impact factor: 6.419

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.